Answers are grounded in this paper and cite their sources.
Background Anaplastic large cell lymphoma (ALCL) comprises biologically distinct entities based on anaplastic lymphoma kinase (ALK) expression, itself a reflection of ALK rearrangement status. Even as genetic alterations have been used to subtype ALCL, the outcomes remain heterogeneous, indicating that current genetic subgrouping does not fully stratify risk ALK-negative ALCL. Methods 149 ALCL biopsy samples (ALK-positive, n = 75; ALK-negative, n = 74) with accompanying clinical data were accrued to identify genomic factors that impact on outcomes. Genetic variants, copy number variants and gene expression profiles were assessed. Results ALK‑negative patients showed inferior overall survival (OS) compared with ALK-positive patients ( p < 0.05). ALK‑negative ALCL that harbored TP53 mutations had the poorest overall and progression-free survival compared to ALK-positive or ALK-negative TP53 ‑wild type cases ( p < 0.05). Mutational burden and copy number variation burden were highest in ALK‑negative, TP53 -mutated cases compared with either of the other groups ( p < 0.05). Finally, we identified a three-gene mutation signature comprised of TP53 , KMT2D and TET2 that significantly stratified overall survival risk across the subtypes. Conclusions Our findings define the differing genomic landscapes underlying ALK-positive and ALK-negative ALCL and point to potential new approaches for risk assessment and targeted therapy strategies.
No takes yet. Share an insight, caveat, or question.
Au-Yeung et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: